Clinical trials: Healthy Elderly
Healthy
A Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and an Adenovirus Serotype 26- Based Vaccine Encoding for the Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF), With and Without Co-administration, in Adults Aged 60 Years and Older in Stable Health
The purpose of this study is to demonstrate the non-inferiority of the concomitant administration of an adenovirus serotype 26- based vaccine encoding for the respiratory syncytial virus pre-fusion F protein (Ad26.RSV.preF) and…
- Trial name
- NCT03339713
- Testing
- Ad26.RSV.preF, Fluarix
- Where
- United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)
A Study of TAK-019 in Healthy Japanese Adults (COVID-19)
TAK-019 is a vaccine in development to protect people against Covid-19. The main aims of the study are to learn if TAK-019 can protect people from Covid-19 and to check for side effects from TAK-019.
- Trial name
- NCT04712110
- Testing
- TAK-019
- Where
- 2 sites in Japan
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Takeda
Herpes Zoster
Study to Evaluate Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine at 9 and 10 Years After Vaccine Administration and Assessment of Re-vaccination With 2 Additional Doses at 10 Years After Initial Vaccination, in Healthy Subjects Aged 60 Years of Age(YOA) and Older
The purpose of this study is to evaluate the persistence of immune response to the HZ vaccine as well as safety up to 10 years after the first dose of initial vaccination course.
- Trial name
- NCT02735915
- Testing
- Herpes Zoster Vaccine GSK1437173A
- Where
- 7 sites in Czechia, Germany and 1 more
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Human Influenza
Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, Including MF59C.1 Adjuvant, in Healthy Adults ≥65 Years of Age
The present study is designed to confirm the safety and immunogenicity of trivalent, surface antigen, inactivated influenza vaccine including MF59C.1 adjuvant, formulation 2013/2014 Northern Hemisphere, in adults ≥65 years of…
- Trial name
- NCT01879540
- Testing
- aTIV
- Where
- Belgium
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Cardiovascular Diseases, Aging
Cardio-vascular Protective Effects of Wolfberry in Middle-aged and Older Adults
This purpose of this study is to assess the impact of consuming wolfberry on cardiovascular risk in Singapore's middle-aged and older adults.
- Trial name
- NCT03535844
- Testing
- Wolfberry, Healthy diet
- Where
- 2 sites in Singapore
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- National University of Singapore
Dengue
Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in Adults
The main purpose of this study is to assess the immunogenicity and safety of the concomitant and sequential administration of yellow fever (YF) vaccine and tetravalent dengue vaccine (TDV) in healthy participants aged 18 to 60…
- Trial name
- NCT03342898
- Testing
- YF-17D, TDV
- Where
- 11 sites in United States
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Takeda
Herpes Zoster
Month 30 & 42 Extension Studies of CRD-004 Primary Study
The safety and immunogenicity of the GSK324332A vaccine has been evaluated up to Month 12 post-vaccination in the primary study.
- Trial name
- NCT00492648
- Testing
- Blood sampling for assay of persistence of immunogenicity
- Where
- Belgium
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Epilepsy
Single-dose and Steady-state Pharmacokinetics of BIA 2-093 and Its Metabolites
The purpose of this study is to determine the effects of age on the pharmacokinetic profile of BIA 2-093 and its active metabolites.
- Trial name
- NCT02172755
- Testing
- BIA 2-093
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Healthy Aging
A Mobile Tai Chi Platform for Fall Prevention in Older Adults - Phase II
This is a single-arm longitudinal feasibility study for older adults that involves a 12-week home-based Tai Chi program and includes four remote and/or in-person data collection visits.
- Trial name
- NCT05006261
- Testing
- Tele-Tai Chi
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Spaulding Rehabilitation Hospital
Healthy Lifestyle
Active Seating System to Lessen Sedentariness in Older Adults: In-home Testing Phase
FitSitt is an innovative device tailored to older adults that increases the convenience of breaking up sedentary activity and incorporating physical activity into in-home daily routines.
- Trial name
- NCT05510297
- Testing
- FitSitt Prototype
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Healthy
A Study of Lasmiditan in Healthy Elderly Participants
The purposes of this study are to evaluate the effect of lasmiditan on blood pressure, as well as to look at the amount of study drug that gets into the blood stream and how long it takes the body to get rid of it in healthy…
- Trial name
- NCT03406260
- Testing
- Lasmiditan
- Where
- 2 sites in United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Pulmonary Disease, Chronic Obstructive
GSK1325756 Relative Bioavailability Study in Healthy Elderly Subjects
This 2-part study will be carried out on healthy elderly subjects to evaluate relative bioavailability of danirixin formulations.
- Trial name
- NCT03457727
- Testing
- Danirixin, Omeprazole
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infections, Papillomavirus, Papillomavirus Vaccines
Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older
This is a multicentre study in which women were planned to receive either the Human Papillomavirus Vaccine (HPV) vaccine or control.
- Trial name
- NCT00294047
- Testing
- Cervarix
- Where
- 75 sites in United States, Australia and 10 more
- Volunteers
- 5,752 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Alzheimer Disease
A Preliminary Study of 18F-AV-45 in Alzheimer's Disease and Healthy Elderly Volunteers
A preliminary study to test how florbetapir F 18 (18F-AV-45) acts in the brains and bodies of healthy elderly people and patients with Alzheimer's Disease (AD) by using a positron emission tomography (PET) scanner.
- Trial name
- NCT01565291
- Testing
- florbetapir F 18
- Where
- 3 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Respiratory Syncytial Viruses, Respiratory Syncytial Virus Infections
A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults
To assess the ability of RSVPreF3 OA investigational vaccine to generate an immune response when given in combination with HZ/su vaccine and its safety in older adults, aged >=50 years of age.
- Trial name
- RSV-OA=ADJ-020 (NCT05966090)
- Testing
- RSVPreF3 OA investigational vaccine, HZ/su vaccine
- Where
- 31 sites in United States, Canada
- Volunteers
- 530 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza Immunization, Healthy Volunteers
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
This was a phase IV, multi-center, open-label study. The study collected serum samples from children 6 months to less than (<) 9 years of age who received Fluzone Quadrivalent vaccine and adults greater than or equal to (>=) 65…
- Trial name
- NCT05050318
- Testing
- Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2021-2022 formulation, Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2021-2022 formulation
- Where
- 2 sites in United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Virtual Reality
Usability, Acceptability, and Safety of Virtual Reality-based Cognitive Intervention
This study aims to determine feasibility, acceptability, and usability, and to assess the safety of using a virtual reality-based software called ''ReCognitionVR'' in healthy volunteers.
- Trial name
- NCT05583903
- Testing
- Virtual Reality Software
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- The Methodist Hospital Research Institute
Meningococcal Vaccine, rLP2086
A Trial to Assess the Safety, Tolerability and Immunogenicity of Repevax and rLP2086 Vaccine When Given Together in Healthy Subjects Aged >=11 to <19 Years.
This study is to look at a new vaccine that might prevent meningococcal disease, and to look at the safety of the new vaccine as well as how it is tolerated when given together with Repevax.
- Conditions
- Meningococcal Vaccine, rLP2086, Repevax, N Meningitidis Serogroup B
- Trial name
- NCT01323270
- Testing
- rLP2086, Repevax, Saline
- Where
- 36 sites in Finland, Germany and 1 more
- Volunteers
- 753 people, healthy volunteers welcome
- Sponsor
- Pfizer
Influenza Caused by the Novel Influenza A (H1N1) Virus
A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults
The purpose of the study is to determine whether CSL425 is a safe and effective vaccine for eliciting an immune response to H1N1 influenza in healthy adults.
- Trial name
- NCT00938639
- Testing
- CSL425
- Where
- Australia
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Seqirus
Hepatitis A
Immunogenicity and Safety of Havrix™ Co-Administered With a Diphtheria, Tetanus and Pertussis and a Haemophilus b Vaccine in Children Aged 15 Months
This is a study to evaluate the immune response and safety of GSK Biologicals 2-dose inactivated hepatitis A vaccine when administered with a diphtheria, tetanus and pertussis combination (DTaP) vaccine and a Haemophilus…
- Trial name
- NCT00197236
- Testing
- Havrix™, Infanrix™, ActHIB™
- Where
- 22 sites in United States
- Volunteers
- 468 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline